You are here: Industry Insights > NICE

News List

Amryt’s Myalepta scores NICE backing for rare lipid disorder pharmatimes
January 21, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Amryt Pharma’s Myalepta (metreleptin) for use within the NHS.
Tecartus wins NICE recommendation for mantle cell lymphoma pharmatimes
January 20, 2021
The UK’s National Centre for Health and Care Excellence (NICE) has recommended Kite’s CAR-T therapy Tecartus (autologous anti-CD19 transduced CD3+ cells) for the treatment of certain adult patients with relapsed or refractory mantle cell lymphoma ...
NICE backs GSK’s Zejula in advanced ovarian cancer pharmatimes
January 18, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of GlaxoSmithKline’s Zejula (niraparib) on the NHS for women with newly diagnosed advanced ovarian cancer.
NICE no for BMS’ Opdivo for head and neck cancer pharmatimes
January 11, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has turned down Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum-based ...
NICE initiates new Innovative Licensing and Access Pathway for medicines europeanpharmaceuticalreview
January 07, 2021
The new pathway developed by NICE for medicines to go from clinical trials to NHS patients is now in action.
NICE collaboration creates new route for medicines approval pharmatimes
January 06, 2021
A collaboration between the UK's National Institute for Health and Care Excellence (NICE), drug regulators, the NHS and equivalent organisation in Scotland has opened a new route for medicine approval in the UK.
Shionogi’s novel antibiotic added to UK’s pilot subscription reimbursement model pharmatimes
December 24, 2020
Shionogi’s novel antibiotic Fetcroja (cefiderocol) has been selected by the UK’s National Institute for Health and Care Excellence (NICE) and the National Health Service England and Improvement (NHSE&I) to be included in a pilot subscription ...
NICE recommends Novartis’ wet AMD drug Beovu pharmatimes
December 16, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ anti-VEGF treatment Beovu (brolucizumab) for routine NHS use in wet age-related degeneration (AMD) patients.
NICE u-turn on Novartis' migraine drug Aimovig pharmatimes
December 15, 2020
In a rare move, NICE has reconsidered its position on Novartis migraine prevention treatment Aimovig (erenumab), now recommending the drug's NHS use in a Final Appraisal Document (FAD) on the back of further analysis submitted by the company.
Alunbrig scores NICE backing for ALK-positive lung cancer pharmatimes
December 14, 2020
Takeda’s Alunbrig (brigatinib) has been recommended by the UK’s National Institute for Health and Care Excellence (NICE) for patients with ALK-positive advanced non-small cell lung cancer (NSCLC).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page